Article

Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene

Received:
Accepted:
Published online:

Abstract

Specifically targeting genomic rearrangements and mutations in tumor cells remains an elusive goal in cancer therapy. Here, we used Cas9-based genome editing to introduce the gene encoding the prodrug-converting enzyme herpes simplex virus type 1 thymidine kinase (HSV1-tk) into the genomes of cancer cells carrying unique sequences resulting from genome rearrangements. Specifically, we targeted the breakpoints of TMEM135–CCDC67 and MAN2A1–FER fusions in human prostate cancer or hepatocellular carcinoma cells in vitro and in mouse xenografts. We designed one adenovirus to deliver the nickase Cas9D10A and guide RNAs targeting the breakpoint sequences, and another to deliver an EGFP-HSV1-tk construct flanked by sequences homologous to those surrounding the breakpoint. Infection with both viruses resulted in breakpoint-dependent expression of EGFP-tk and ganciclovir-mediated apoptosis. When mouse xenografts were treated with adenoviruses and ganciclovir, all animals showed decreased tumor burden and no mortality during the study. Thus, Cas9-mediated suicide-gene insertion may be a viable genotype-specific cancer therapy.

  • Subscribe to Nature Biotechnology for full access:

    $250

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    & Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

  2. 2.

    et al. Novel fusion transcripts associate with progressive prostate cancer. Am. J. Pathol. 184, 2840–2849 (2014).

  3. 3.

    , , & Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174–182 (2005).

  4. 4.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

  5. 5.

    , , & Concerning RNA-guided gene drives for the alteration of wild populations. eLife 3, 03401 (2014).

  6. 6.

    et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).

  7. 7.

    , , , & A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 22, 55–61 (1982).

  8. 8.

    , & Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 87, 189–198 (2000).

  9. 9.

    et al. Genomic copy number variations in the genomes of leukocytes predict prostate cancer clinical outcomes. PLoS One 10, e0135982 (2015).

  10. 10.

    et al. Discovery and classification of fusion transcripts in prostate cancer and normal prostate tissue. Am. J. Pathol. 185, 1834–1845 (2015).

  11. 11.

    , , , & Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res. 40, 524–534 (1980).

  12. 12.

    et al. Characterization of chromosome changes in two human prostatic carcinoma cell lines (PC-3 and DU145) using chromosome painting and comparative genomic hybridization. Cancer Genet. Cytogenet. 96, 123–128 (1997).

  13. 13.

    et al. MAN2A1-FER fusion gene is expressed by human liver and other tumor types and has oncogenic activity in mice. Gastroenterology (2017).

  14. 14.

    & The hallmarks of cancer. Cell 100, 57–70 (2000).

  15. 15.

    et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16, 142–147 (2015).

  16. 16.

    et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013).

  17. 17.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

  18. 18.

    & Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev. 3, 499–503 (1993).

  19. 19.

    , , , & A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 7, 1034–1038 (2000).

  20. 20.

    et al. p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3. J. Biol. Chem. 287, 16890–16902 (2012).

  21. 21.

    et al. Integrin alpha 7 interacts with high temperature requirement A2 (HtrA2) to induce prostate cancer cell death. Am. J. Pathol. 177, 1176–1186 (2010).

  22. 22.

    , & (−)-Epigallocatechin-3-gallate induces Du145 prostate cancer cell death via downregulation of inhibitor of DNA binding 2, a dominant negative helix-loop-helix protein. Cancer Sci. 101, 707–712 (2010).

  23. 23.

    et al. Interaction of integrin-linked kinase and miniature chromosome maintenance 7-mediating integrin alpha7 induced cell growth suppression. Cancer Res. 70, 4375–4384 (2010).

  24. 24.

    , , , & CSR1 induces cell death through inactivation of CPSF3. Oncogene 28, 41–51 (2009).

  25. 25.

    , , & Inhibition of prostate cancer growth and metastasis using small interference RNA specific for minichromosome complex maintenance component 7. Cancer Gene Ther. 17, 694–699 (2010).

  26. 26.

    et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 67, 8043–8050 (2007).

  27. 27.

    et al. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J. Natl. Cancer Inst. 99, 868–880 (2007).

  28. 28.

    et al. CSR1 suppresses tumor growth and metastasis of prostate cancer. Am. J. Pathol. 168, 597–607 (2006).

  29. 29.

    et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538–542 (2015).

  30. 30.

    et al. Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J. Pathol. 230, 184–193 (2013).

  31. 31.

    et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 25, 1090–1098 (2006).

  32. 32.

    et al. Expression of myopodin induces suppression of tumor growth and metastasis. Am. J. Pathol. 164, 1799–1806 (2004).

  33. 33.

    , , , & Ductular reaction after submassive necrosis in humans: special emphasis on analysis of ductular hepatocytes. Am. J. Pathol. 149, 439–448 (1996).

  34. 34.

    et al. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am. J. Pathol. 183, 1960–1970 (2013).

  35. 35.

    et al. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. Am. J. Pathol. 159, 1603–1612 (2001).

Download references

Acknowledgements

We thank S. Zheng for technical support. This work was supported by grants from the National Cancer Institute to JHL (RO1 CA098249 to J.-H.L.), the Department of Defense (W81XWH-16-1-0364) to J.-H.L. and the University of Pittsburgh Cancer Institute to J.-H.L., G.K.M. and J.B.N.

Author information

Affiliations

  1. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

    • Zhang-Hui Chen
    • , Yan P Yu
    • , Ze-Hua Zuo
    • , George K Michalopoulos
    • , Satdatshan Monga
    •  & Jian-Hua Luo
  2. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

    • Joel B Nelson
  3. Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

    • Silvia Liu
    •  & George Tseng

Authors

  1. Search for Zhang-Hui Chen in:

  2. Search for Yan P Yu in:

  3. Search for Ze-Hua Zuo in:

  4. Search for Joel B Nelson in:

  5. Search for George K Michalopoulos in:

  6. Search for Satdatshan Monga in:

  7. Search for Silvia Liu in:

  8. Search for George Tseng in:

  9. Search for Jian-Hua Luo in:

Contributions

J.-H.L. and Y.P.Y. conceived the concept of the project and devised the research strategy. Z.-H.C. and Z.-H.Z. performed most experiments, S.M. provided materials, G.K.M. and J.B.N. provided expertise and advice on the biology of and therapies for liver cancer and prostate cancer. S.L. and G.T. performed biostatistics and bioinformatics analyses.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Jian-Hua Luo.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–3 and Supplementary Tables 1–7